Taro Pharma (TARO) Reports Q1 Loss of $11.37 on Revenues of $117.6M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Taro Provides Results for Quarter Ended June 30, 2020
July 29, 2020 5:00 PM EDTQuarter reflects One-Time Charge for Global Resolution with DOJ
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro) today provided unaudited financial results for the quarter ended June 30, 2020.
Quarter ended June 30, 2020 Highlights - compared to Quarter ended June 30, 2019
Net sales of $117.6 million, decreased $43.7 million. Gross profit of $64.9 million decreased $36.8 million, and as a percentage of net sales was 55.2% compared to 63.1%. Research and development expenses of $12.9 million decreased slightly from the prior year. Selling, marketing, general and administrative... More